Critical Limb Ischemia Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027
4 mins read

Critical Limb Ischemia Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027

Global Critical Limb Ischemia Treatment Market – Snapshot

The global critical limb ischemia treatment market is driven by rise in prevalence of critical limb ischemia. Growth of the market is also attributed to increase in awareness about critical limb ischemia and rich product pipeline.

Critical limb ischemia (CLI) is a severe peripheral arterial disease (PAD), wherein chronic inflammation associated with atherosclerosis (progressive thickening of arteries lining) causes reduced blood flow to the extremities (legs, feet, and hands), leading to severe pain and ulcers or sore. Major risk factors for critical limb ischemia comprise aging (people aged 60 or over are at high risk of developing this diseased condition), obesity, diabetes, high cholesterol level, smoking, sedentary lifestyle, and high blood pressure. Critical limb ischemia is associated with symptoms such as ischemic rest pain, gangrene, or tissue loss. Rise in prevalence of critical limb ischemia is anticipated to increase demand for therapeutics, which in turn is expected to drive the global critical limb ischemia treatment market. According to recent study, around 2 million to 3 million people suffer from critical limb ischemia in the U.S. Moreover, increase in health care expenditure and rise in the number of clinical trials are likely to propel the global critical limb ischemia treatment market.

Request Sample Of Report –    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2770

critical limb ischemia treatment market

The global critical limb ischemia treatment market has been segmented based on treatment and region. In terms of treatment, the global market has been classified into devices and medications. The devices segment accounted for major share of the global market in terms of revenue in 2018. The segment is projected to expand at a high CAGR during the forecast period due to increase in demand for various type of stents and balloons in the treatment of critical limb ischemia. The devices segment has been categorized into embolic protection devices and peripheral dilatation systems. The peripheral dilatation systems segment dominated the devices segment in 2018, as dilation devices and stents provide dilation effectively and protect the artery wall. These devices are the most frequently used treatments for critical limb ischemia and provide certain advantage over traditional treatments. The peripheral dilatation systems segment has been bifurcated into balloon dilators and vascular stents. The vascular stents segment dominated the global market in 2018. The trend is likely to continue during the forecast period. The medications segment includes antiplatelet drugs, antihypertensive agents, lipid-lowering agents, antithrombotic agents, and others.

Request the Coronavirus Impact Analysis on this Market –   https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2770

In terms of region, the global critical limb ischemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018 and is projected to gain market share from 2019 to 2027. The market in North America is driven by increase in incidence of critical limb ischemia, new product approvals, strong product pipeline, and rise in health care expenditure. The critical limb ischemia treatment market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Japan dominated the market in the region in 2018 due to high population of patients with critical limb ischemia.

Buy this Research Report Now –   https://www.transparencymarketresearch.com/checkout.php?rep_id=2770&ltype=S

Major players operating in the global critical limb ischemia treatment market include Medtronic plc, Boston Scientific Corporation, Cesca Therapeutics, Inc., Abbott Laboratories, Pluristem Therapeutics, Inc., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc. These companies have adopted the strategy of acquisition and collaboration to strengthen their positions in the global market.

More Trending Reports by Transparency Market Research –   https://www.biospace.com/article/non-opioid-pain-patch-market-need-for-non-addictive-chronic-pain-treatment-to-foster-growth/